November 1, 2023 - Regulatory SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate
October 12, 2023 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
October 11, 2023 - Regulatory SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
October 3, 2023 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP
September 12, 2023 - Regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
September 4, 2023 - Regulatory SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
August 17, 2023 - Non-regulatory SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 20, 2023 - Non-regulatory SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 14, 2023 - Non-regulatory SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients
June 29, 2023 - Non-regulatory SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4
May 25, 2023 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023
April 24, 2023 - Regulatory SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis
April 17, 2023 - Non-regulatory SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023
April 3, 2023 - Regulatory The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member
March 28, 2023 - Non-regulatory SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023
February 1, 2023 - Regulatory Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
